Floatz logo

9 assets in Nodular Lymphocyte Predominant Hodgkin Lymphoma

Therapeutic assets addressing Nodular Lymphocyte Predominant Hodgkin Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Adriamycin
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)P3BBB (72)
Prednisone
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)P3BBB (72)
Cyclophosphamide
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)P3BB (71)
Vincristine Sulfate
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)P2/3BB (67)
Rituximab
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)P2/3BB (65)
Recombinant Human Hyaluronidase
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)P2/3B (62)
Azacitidine
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)P2/3B (57)
Fludeoxyglucose
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Mosunetuzumab
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)P2CCC (53)